Featured in the October edition of the Journal of Thoracic Oncology, data from the Tarceva Lung Cancer Survival Treatment, or TRUST, confirms the safety and efficacy profile of erlotinib, a highly potent oral active, reversible inhibitor of epidermal growth factor receptor tyrosine-kinase activity in a large heterogeneous non-small cell lung cancer population.
TRUST study data confirms safety and efficacy of erlotinib for advanced lung cancer
- EurekAlert
- 1. 10 2010 (06:00)